Application of ioversol in preparation of body surface contrast agent and body surface contrast agent
By using iodofol aqueous gel as a contrast agent, the uncertainty of incision design in parotid gland tumor resection surgery was resolved, enabling accurate incision location and smooth surgical execution.
Patent Information
- Application Number
- CN202210914460.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-01
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-08-01
AI Technical Summary
In parotid gland tumor resection surgery, the preoperative design of the neck crease incision is difficult to assess and uncertain, which affects the feasibility and difficulty of the surgery.
An aqueous gel containing iodofol was used as a contrast agent for body surface treatment. By mixing ultrasound coupling agent and iodofol injection solution, a contrast agent for body surface treatment was prepared to accurately locate incision sites and assess anatomical structures.
It provides accuracy and intuitiveness in preoperative incision design, helping surgeons determine the positional relationship between the incision and the tumor, as well as the difficulty of the approach, ensuring the smooth progress of the surgery.
Smart Images

Figure CN115177748B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of contrast diagnosis, in particular to an application of ioversol in preparing a body surface contrast agent and the body surface contrast agent. Background Art
[0002] The cosmetic incision of parotid gland tumor resection surgery has always been a research hotspot and clinical difficulty in oral and maxillofacial surgery. In recent years, scholars at home and abroad have proposed using the neck surface anatomical landmark - the neck wrinkle as an incision for parotid gland lower pole tumor resection, thereby achieving the purpose of effectively concealing the incision scar. At present, whether the patient is an indication for neck wrinkle incision and whether the neck wrinkle incision design is reasonable are mainly judged by the surgeon based on experience. The assessment of the feasibility and difficulty of the operation is highly subjective, which brings uncertainty to the smooth progress of the operation. Therefore, providing a product that can improve the preoperative design of neck wrinkle incision is an urgent problem to be solved.
[0003] In view of this, the present invention is proposed. Summary of the invention
[0004] The first object of the present invention is to provide a body surface contrast agent to alleviate the problem of difficulty in designing the neck line incision before the operation in the parotid gland tumor removal operation.
[0005] The second purpose of the present invention is to provide the use of ioversol or a preparation containing ioversol in the preparation of a body surface contrast agent, and a product for parotid tumor resection surgery.
[0006] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:
[0007] According to one aspect of the present invention, the present invention provides a body surface contrast agent, wherein the body surface contrast agent is an aqueous gel containing ioversol.
[0008] Preferably, the iodine content of the body surface contrast agent is at least 30 mg / mL;
[0009] Preferably, the iodine content in the body surface contrast agent is 30-110 mg / mL.
[0010] Preferably, it is mainly prepared by mixing an ultrasonic coupling agent and ioversol injection;
[0011] Preferably, the volume ratio of the ultrasonic coupling agent to the ioversol injection is at least 10:1;
[0012] Preferably, the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:1 to 10:5.
[0013] According to another aspect of the present invention, the present invention also provides a kit for body surface imaging, the kit comprising independently packaged aqueous gel, and independently packaged ioversol or a preparation containing ioversol.
[0014] Preferably, the aqueous gel is selected from an ultrasonic coupling agent;
[0015] Preferably, the preparation containing ioversol is selected from ioversol injection.
[0016] According to another aspect of the present invention, the present invention also provides the use of ioversol or a preparation containing ioversol in the preparation of a body surface contrast agent, wherein the body surface contrast agent is an aqueous gel;
[0017] Preferably, the iodine content of the body surface contrast agent is at least 30 mg / mL;
[0018] Preferably, the iodine content in the body surface contrast agent is 30-110 mg / mL.
[0019] Preferably, the preparation containing ioversol is ioversol injection.
[0020] Preferably, the preparation of the body surface contrast agent comprises mixing an ultrasound coupling agent and ioversol or a preparation containing ioversol to obtain the body surface contrast agent;
[0021] Preferably, the preparation containing ioversol is ioversol injection, and the volume ratio of the ultrasonic coupling agent to the ioversol injection is at least 10:1;
[0022] Preferably, the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:1 to 10:5.
[0023] According to another aspect of the present invention, the present invention also provides the use of the above-mentioned body surface contrast agent, or a kit for body surface contrast in the preparation of a product for parotid tumor resection surgery.
[0024] According to another aspect of the present invention, the present invention also provides a product for parotid tumor resection surgery, the product comprising the above-mentioned body surface contrast agent, or a kit for body surface contrast.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] The body surface contrast agent provided by the present invention is an aqueous gel containing ioversol. The gel component in the body surface contrast agent can effectively reduce the fluidity of the contrast agent, so that the marking effect of the body surface contrast agent remains unchanged during the scanning time; ioversol provides iodine element to the body surface contrast agent, which can form a radiation-blocking effect on X-rays.
[0027] The surface contrast agent provided by the present invention uses ioversol in the form of an aqueous gel, which can accurately locate the incision during contrast imaging, and can make the preoperative evaluation of the expected incision more accurate and intuitive. The surface contrast agent helps the operator to accurately evaluate the relative position of the expected incision and the tumor before the operation, evaluate the difficulty of the expected approach, and the anatomical structure that may be involved and the feasibility of the expected incision, which helps the smooth progress of the operation and will play a very important role in the parotid tumor resection involving neck cosmetic incision.
[0028] The body surface contrast agent provided by the present invention has a simple method of use, accurate marking, and is easy to promote; and after the body surface marking contrast gel is used, the body surface contrast agent can be easily wiped off the skin using a paper towel, a handkerchief, etc., and is easy to clean. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0030] Figure 1a The CT angiography image of the arterial phase of enhanced CT scanning after the surface contrast agent provided by the embodiment of the present invention is applied to the body surface;
[0031] Figure 1b The CT contrast image of the venous phase of enhanced CT scanning after the surface contrast agent provided by the embodiment of the present invention is applied to the surface of the body;
[0032] Figure 1c The CT contrast image of the delayed period during enhanced CT scanning after the surface contrast agent provided by the embodiment of the present invention is applied to the surface of the body;
[0033] Figure 1d The three-dimensional reconstruction effect of the body surface contrast agent provided by the embodiment of the present invention in the arterial phase of the enhancement phase;
[0034] Figure 1e The three-dimensional reconstruction effect of the body surface contrast agent provided by the embodiment of the present invention in the enhanced venous phase;
[0035] Figure 1f The three-dimensional reconstruction effect of the body surface contrast agent provided by the embodiment of the present invention in the delayed period of the enhancement phase;
[0036] Figure 2a This is a CT angiographic image of the arterial phase of enhanced CT scanning after iodized oil injection liquid surface coating;
[0037] Figure 2bThis is a CT contrast image taken during the venous phase of enhanced CT scanning after iodized oil injection liquid is applied to the surface;
[0038] Figure 2c This is a CT contrast image taken during the delayed period of enhanced CT scanning after iodized oil injection liquid surface coating;
[0039] Figure 3 The fluidity of the iodized oil injection liquid after coating is shown in the figure;
[0040] Figure 4a The effect of the body surface contrast agent prepared in Example 4 after being applied to the skin;
[0041] Figure 4b This is the effect of the body surface contrast agent prepared in Example 5 after being applied to the skin;
[0042] Figure 4c This is the effect of the body surface contrast agent prepared in Example 6 after being applied to the skin;
[0043] Figure 4d This is the effect of the surface contrast agent prepared in Example 7 after being applied to the skin. DETAILED DESCRIPTION
[0044] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0045] According to one aspect of the present invention, the present invention provides a body surface contrast agent, which is an aqueous gel containing ioversol.
[0046] Conventional contrast agents are chemicals injected (or taken) into human tissues or organs to enhance the effect of image observation. The density of these products is higher or lower than that of the surrounding tissues, and the contrast formed is used to display images with certain instruments. The contrast agent provided by the present invention is applied to the body surface, that is, applied to the surface or surface of the body, so the present invention provides a body surface contrast agent.
[0047] The main component of the body surface contrast agent provided by the present invention includes ioversol, whose chemical name is N, N'-bis (2, 3-dihydroxypropyl) -5- [N- (2-hydroxyethyl) glycolylamino] -2, 4, 6-triiodo-1, 3-benzenedicarbamide. Molecular formula: C 18 H 24 I 3 N 3 O 9 Its main function is to block X-rays.
[0048] Ioversol is mainly used for various vascular radiological angiography examinations, including cerebral angiography, peripheral artery angiography, visceral artery, renal artery and aortography, cardiovascular angiography including coronary angiography, arterial and venous digital subtraction angiography, etc. Intravenous urography and CT enhanced examination. Ioversol is mainly used for in vivo angiography, and the conventional method of use is intravenous injection.
[0049] Gel refers to a thick liquid or semisolid preparation with gel properties made from raw materials and excipients that can form gel. The gel matrix is a single-phase dispersion system and can be divided into aqueous and oily. The surface contrast agent provided by the present invention is an aqueous gel.
[0050] The present invention applies ioversol used for in vivo contrast imaging in vitro, and uses an aqueous gel dosage form as a surface contrast agent. Because the gel component in the surface contrast agent can effectively reduce the fluidity of the contrast agent, the marking effect of the surface contrast agent is maintained unchanged during the scanning time, ensuring that the position of the surface contrast agent does not change when the patient is undergoing contrast imaging. In particular, when performing a spiral CT examination in the supine position, the use of the surface contrast agent of the present invention can prevent the position of the surface contrast agent located at the neck incision line from changing. The surface contrast agent can make the preoperative evaluation of the expected incision more accurate and intuitive, which helps the smooth progress of the operation; the surface marking contrast gel is simple to use, has accurate marking, and is easy to promote.
[0051] The surface contrast agent provided by the present invention can be clearly displayed on CT images and can accurately position the incision before surgery, thereby effectively helping the surgeon to judge the positional relationship between the expected incision and the tumor, evaluate the difficulty of the expected approach, and the possible anatomical structures involved and the feasibility of the expected incision, and will play a very important role in parotid tumor resection involving neck cosmetic incision.
[0052] After the surface contrast agent is used as the surface marker contrast gel, it can be easily wiped off from the skin using a tissue, a handkerchief, etc., and is easy to clean.
[0053] The excipients, the combination of excipients and the ratio of excipients constituting the aqueous gel of the present invention can be selected from conventional forms acceptable in the art. The specific excipients, the combination of excipients and the ratio of excipients can be carried out according to methods well known in the art and recorded in various general and more specific teaching materials, references, process manuals, product descriptions and standard documents, etc., and the present invention does not limit this.
[0054] The excipients included in the body surface contrast agent provided by the present invention may include, for example, but are not limited to, one or more of water, glycerol, propylene glycol, glycerol, ethanol, cellulose derivatives, chitosan, carbomer, alginate, tragacanth gum, gelatin and starch. The body surface contrast agent may optionally include other pharmaceutical excipients for enhancing the performance of the body surface contrast agent, such as but not limited to pH regulators, moisturizers, antibacterial agents, antioxidants, thickeners, solubilizers, cosolvents, colorants, flow aids, anti-caking agents, fragrances and antioxidant synergists.
[0055] The auxiliary material composition used to form the aqueous gel in the body surface contrast agent provided by the present invention can be, for example, but not limited to: water, propylene glycol and ethanol; or, carbomer, triethanolamine, glycerol and ethanol; carbomer, glycerol, glycerol, chitosan, sodium hydroxide and water; or, carbomer, glycerol, sodium hydroxide, methyl benzoate, ethanol and water; or, water, propylene glycol and ethanol, etc.
[0056] In some optional embodiments, the iodine content in the body surface contrast agent is at least 30 mg / mL, and the iodine content in the body surface contrast agent is preferably 30-110 mg / mL, for example, it can be but not limited to 30, 40, 50, 60, 70, 80, 90, 100 or 110 mg / mL.
[0057] In some optional embodiments, the body surface contrast agent is mainly prepared by mixing an ultrasonic coupling agent and an ioversol injection solution. The ultrasonic coupling agent provides an aqueous gel component for the body surface contrast agent, and the ioversol injection solution provides ioversol for the body surface contrast agent.
[0058] Ultrasonic coupling agent is a medical product composed of a new generation of aqueous polymer gel, which is an aqueous gel. Since ultrasonic coupling agent has been widely used in the medical field, its formula has been verified in the medical field, is non-toxic and harmless to the human body, and is not easy to dry or become rancid. It also has the advantages of clear ultrasonic imaging, suitable viscosity, no greasiness, easy sliding of the probe, moistening the skin, eliminating air on the skin surface, good lubrication and easy deployment. The ultrasonic coupling agent can optionally be any commercially available ultrasonic coupling agent acceptable in the medical field, such as but not limited to ultrasonic coupling agents used for type A, type B, and type M ultrasonic diagnostic instruments, and the present invention does not limit this.
[0059] Ioversol injection, a Western medicine name, is a prescription contrast agent. Ioversol injection is a sterile aqueous solution of iooversol, containing an appropriate amount of tromethamine as a buffer and an appropriate amount of calcium disodium ethylenediaminetetraacetate as a stabilizer. Each 20mL contains 13.56g of iooversol, and each 1mL of iooversol injection contains 320mg of iodine.
[0060] In some optional embodiments, the volume ratio of the ultrasonic coupling agent and ioversol injection is at least 10:1. The appropriate ratio of the ultrasonic coupling agent and ioversol injection can optimize the use effect of the surface contrast agent. If the ioversol injection content is too high, the fluidity of the surface contrast agent is enhanced, which is not conducive to the effective retention of the surface contrast agent on the body surface; if the ultrasonic coupling agent content is too high, the ioversol content in the surface contrast agent is too low, which is not conducive to contrast imaging.
[0061] Therefore, in some preferred embodiments, the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:1 to 10:5, for example, but not limited to, 10:1, 10:2, 10:3, 10:4 or 10:5.
[0062] According to another aspect of the present invention, the present invention also provides a kit for body surface imaging, the kit comprising an independently packaged aqueous gel and independently packaged ioversol or a preparation containing ioversol. When the kit is used, the independently packaged aqueous gel and the independently packaged ioversol or a preparation containing ioversol are uniformly mixed to obtain an aqueous gel containing ioversol as a body surface contrast agent.
[0063] When the kit is used, after mixing the aqueous gel and ioversol or a preparation containing ioversol, the iodine content in the obtained body surface contrast agent is preferably at least 30 mg / mL, more preferably 30-110 mg / mL, for example, but not limited to 30, 40, 50, 60, 70, 80, 90, 100 or 110 mg / mL.
[0064] The aqueous gel in the kit can be selected from aqueous gels acceptable for body surface in the medical field, and the present invention does not limit this. The present invention does not limit the composition of the aqueous gel in the kit, and its composition can be, for example, but not limited to: water, propylene glycol and ethanol; or, carbomer, triethanolamine, glycerol and ethanol; carbomer, glycerol, glycerol, chitosan, sodium hydroxide and water; or, carbomer, glycerol, sodium hydroxide, methyl benzoate, ethanol and water; or, water, propylene glycol and ethanol, etc. Based on the above description of the effects of the ultrasonic coupling agent, the aqueous gel in the kit is preferably an ultrasonic coupling agent.
[0065] The ioversol or the preparation containing ioversol contained in the kit can be selected from ioversol that meets the pharmacopoeia standards, or can be selected from the preparation containing ioversol. The preparation containing ioversol is preferably ioversol injection.
[0066] Based on the above inventive concept, according to another aspect of the present invention, the present invention also provides the use of ioversol or a preparation containing ioversol in preparing a body surface contrast agent. Ioversol or a preparation containing ioversol can be optionally directly prepared into a body surface contrast agent, or as a component independently packaged in a kit, used to prepare a body surface contrast agent when used.
[0067] Ioversol or a preparation containing ioversol is used to prepare a surface contrast agent. Preferably, the iodine content in the prepared surface contrast agent is at least 30 mg / mL, more preferably 30-110 mg / mL, for example, but not limited to 30, 40, 50, 60, 70, 80, 90, 100 or 110 mg / mL.
[0068] In some optional embodiments, ioversol injection is used to prepare a surface contrast agent, and the preparation of the surface contrast agent preferably includes mixing an ultrasound coupling agent and ioversol or a preparation containing ioversol to obtain the surface contrast agent, wherein the ultrasound coupling agent causes the surface contrast agent to form an aqueous gel dosage form.
[0069] In some optional embodiments, in the application, an ultrasonic coupling agent is used as a component of an aqueous gel dosage form of a body surface contrast agent, and ioversol injection provides ioversol as a body surface contrast agent. The volume ratio of the ultrasonic coupling agent to ioversol injection is at least 10:1, preferably 10:1 to 10:5, for example, it can be but not limited to 10:1, 10:2, 10:3, 10:4 or 10:5.
[0070] According to another aspect of the present invention, the present invention also provides the use of the above-mentioned body surface contrast agent or the above-mentioned kit for body surface contrast in the preparation of a product for parotid tumor resection surgery.
[0071] According to another aspect of the present invention, the present invention also provides a product for parotid gland tumor removal surgery, the product comprising the above-mentioned body surface contrast agent, or the above-mentioned kit for body surface imaging. It is understood that the product for parotid gland tumor removal surgery may also include optional surgical reagents, drugs or surgical instruments acceptable in the art.
[0072] The above-mentioned surface contrast agent or the above-mentioned kit for surface contrast imaging is used to prepare products for parotid gland tumor resection surgery, or the prepared products can be used for preoperative neck line incision design, which can make the preoperative evaluation of the expected incision more accurate and intuitive, and help the smooth progress of the operation. The products used for parotid gland tumor resection surgery can effectively help the surgeon determine the positional relationship between the expected incision and the tumor, help to accurately evaluate the difficulty of the expected approach, as well as the anatomical structures that may be involved and the feasibility of the expected incision, and will play a very important role in parotid gland tumor resection involving neck cosmetic incisions.
[0073] The technical scheme and technical effects of the present invention are further explained below in conjunction with preferred embodiments.
[0074] The ultrasonic coupling agent used in the following examples is the medical ultrasonic coupling agent produced by Beijing Dafu Xingye Jingsheng Technology Co., Ltd.; the ioversol injection is the ioversol injection produced by Jiangsu Hengrui.
[0075] Example 1
[0076] This embodiment provides a body surface contrast agent, which is obtained by mixing an ultrasonic coupling agent and ioversol injection, and the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:1.
[0077] Example 2
[0078] This embodiment provides a body surface contrast agent, which is obtained by mixing an ultrasonic coupling agent and ioversol injection, and the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:2.
[0079] Example 3
[0080] This embodiment provides a body surface contrast agent, which is obtained by mixing an ultrasonic coupling agent and ioversol injection, and the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:3.
[0081] Example 4
[0082] This embodiment provides a body surface contrast agent, which is obtained by mixing an ultrasonic coupling agent and ioversol injection, and the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:4.
[0083] Example 5
[0084] This embodiment provides a body surface contrast agent, which is obtained by mixing an ultrasonic coupling agent and ioversol injection, and the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:5.
[0085] Example 6
[0086] This embodiment provides a body surface contrast agent, which is obtained by mixing an ultrasonic coupling agent and ioversol injection, and the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:6.
[0087] Example 7
[0088] This embodiment provides a body surface contrast agent, which is obtained by mixing an ultrasonic coupling agent and ioversol injection, and the volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:7.
[0089] Comparative Example 1
[0090] Iodized oil injection was purchased from Yantai Luyin.
[0091] Comparative Example 2
[0092] Ioversol injection (Jiangsu Hengrui).
[0093] Effect Example 1
[0094] The contrast agent of Example 3 is applied to the incision position expected by the surgeon through a medical irrigator. The surface contrast agent provided by Example 3 can accurately and evenly cover the incision line position. Figure 1a , Figure 1b , Figure 1c , Figure 1d , Figure 1e and Figure 1f shown.
[0095] Figure 1a to Figure 1c They are the contrast effects of the surface contrast agent of Example 3 in the arterial phase, venous phase, and delayed phase (about 5 minutes in total) of the enhancement phase. The gel marking time point is before the start of the irradiation. In this group of figures, it can be seen that the contrast results of the surface contrast agent of Example 3 within the time required for irradiation (the position indicated by the arrow) are clear and can meet the diagnostic requirements. The contrast results do not change significantly during the scanning time.
[0096] Figure 1d to Figure 1f They are the three-dimensional reconstruction effects of the body surface contrast agent in Example 3 in the enhanced arterial phase, venous phase, and delayed phase, which can clearly show the positional relationship between the incision mark (the position indicated by arrow 1) and the tumor (the position indicated by arrow 2).
[0097] Effect Example 2
[0098] The contrast agent of Comparative Example 1 was applied to the incision position expected by the operator through a medical irrigator. The CT contrast image after the iodized oil injection liquid surface was applied was as follows: Figure 2a , Figure 2b and Figure 2c shown.
[0099] Figure 2a , Figure 2b and Figure 2c These are the contrast effects of iodized oil injection in the arterial phase, venous phase, and delayed phase (about 5 minutes in total) during enhanced CT scanning. The arrows indicate the contrast results of iodized oil injection. Figure 2a and Figure 2b In the case of iodized oil injection, the liquid is thin and not clearly displayed. Figure 2c In the experiment, the iodized oil injection obviously flowed downward in the shape of water drops.
[0100] Effect Example 3
[0101] The fluidity of iodized oil injection after application on the neck wrinkles is shown as follows Figure 3As shown in the figure, arrow 1 shows the appearance after applying iodized oil injection on the neck wrinkles, and arrow 2 shows the flow of iodized oil injection to the back of the neck after application. Iodized oil injection is an oily contrast medium, while ioversol is an aqueous contrast medium. The fluidity of aqueous contrast medium is stronger than that of oily contrast medium, so the effect of using ioversol alone for surface contrast imaging is less ideal.
[0102] Effect Example 4
[0103] The contrast agents provided in Examples 4 to 7 were applied to the skin surface by a medical irrigator, and their fluidity on the skin surface was observed. The results are as follows: Figure 4a , 4b , 4c and 4d, from Figure 4a From Figure 2, it can be seen that when the ratio of ioversol injection to surface contrast agent is too high, the fluidity of surface contrast agent will become stronger and it will be difficult to maintain the initial marking effect. When the volume ratio of ultrasound coupling agent to ioversol injection is 10:6 ( Figure 4c ) and 10:7 (4d), it can be clearly seen that the contrast agent on the surface of the body has a tendency to flow. Therefore, the effect is better when the volume ratio of ultrasound coupling agent to ioversol injection is not less than 10:5.
[0104] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. Application of ioversol injection in the preparation of a body surface contrast agent, wherein the body surface contrast agent is an aqueous gel; the body surface contrast agent is used for parotid tumor resection surgery; The preparation of the body surface contrast agent comprises mixing an ultrasonic coupling agent and an ioversol injection solution to obtain the body surface contrast agent; The volume ratio of the ultrasonic coupling agent to the ioversol injection is 10:1-10:5, and the iodine content in the body surface contrast agent is 30-110 mg / mL.
